GGrantIndex
← Leaderboards

Barbara A. Konkle

University Of Pennsylvania

$9,271,745
Attributed
$11,874,412
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY200516
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$9,532,359 · 7
CDC$2,342,053 · 2

By mechanism

U01$4,012,334 · 3
R01$3,814,049 · 1
R34$1,403,584 · 2
K12$1,194,762 · 1
RC1$996,583 · 1
R21$453,100 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Base

Research focus

BasePharmaceutical PreparationsErythrocytesFunctional DisorderPlasmaAdultPreventSickle Cell AnemiaAnticoagulantsBlood PlateletsAdhesivenessDesignAcetylcysteinePainMouse ModelThrombocytopeniaSafetyLaboratoriesMorbidity - Disease RateSeveritiesHemolysisAntioxidantsHeparinVon Willebrand Factor

Grant awards (28)

von Willebrand Factor in Sickle Cell Disease Pathophysiology$729,091
R01 · FY2016 · HL
A Pilot Study of N-acetylcysteine in Sickle Cell Disease Vaso-Occlusive Crisis$397,499
R34 · FY2016 · HL · contact PI
von Willebrand Factor in Sickle Cell Disease Pathophysiology$148,808
R01 · FY2016 · HL
von Willebrand Factor in Sickle Cell Disease Pathophysiology$718,154
R01 · FY2015 · HL
A Pilot Study of N-acetylcysteine in Sickle Cell Disease Vaso-Occlusive Crisis$405,055
R34 · FY2015 · HL · contact PI
von Willebrand Factor in Sickle Cell Disease Pathophysiology$731,326
R01 · FY2014 · HL
von Willebrand Factor in Sickle Cell Disease Pathophysiology$710,432
R01 · FY2013 · HL
A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population$189,958
U01 · FY2013 · DD
von Willebrand Factor in Sickle Cell Disease Pathophysiology$776,238
R01 · FY2012 · HL
LMWH for Post-partum Prophylaxis in Women at Risk of Venous Thrombosis$300,699
R34 · FY2012 · HL · contact PI
A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population$199,953
U01 · FY2012 · DD
A Pilot Study of LMWH for Post-Partum Prophylaxis in Women at Risk of Venous Thro$300,331
R34 · FY2011 · HL · contact PI
A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population$200,000
U01 · FY2011 · DD
Novel Biomarkers Predictive of Heparin-Induced Thrombocytopenia$499,110
RC1 · FY2010 · HL · contact PI
Novel Biomarkers Predictive of Heparin-Induced Thrombocytopenia$497,473
RC1 · FY2009 · HL · contact PI
Mentored career development in clinical research in non-malignant hematology$397,189
K12 · FY2008 · HL · contact PI
Age Dependent Thrombotic Risk Factors in Heparin-induced Thrombocytopenia$239,050
R21 · FY2008 · HL · contact PI
Prevention of the Complications of Bleeding Disorders Through HTCS$876,076
U01 · FY2007 · DD · contact PI
Mentored career development in clinical research in non-malignant hematology$397,589
K12 · FY2007 · HL · contact PI
Transfusion/Hemostasis clinical research network$214,236
U01 · FY2007 · HL · contact PI
Age Dependent Thrombotic Risk Factors in Heparin-induced Thrombocytopenia$214,050
R21 · FY2007 · HL · contact PI
Prevention of the Complications of Bleeding Disorders Through HTCS$876,066
U01 · FY2006 · DD · contact PI
Mentored career development in clinical research in non-malignant hematology$399,984
K12 · FY2006 · HL · contact PI
Transfusion/Hemostasis Clinical Research Network$285,018
U01 · FY2006 · HL · contact PI
Transfusion/Hemostasis Clinical Research Network$289,250
U01 · FY2005 · HL
Transfusion/Hemostasis Clinical Research Network$286,700
U01 · FY2004 · HL
Transfusion/Hemostasis Clinical Research Network$295,077
U01 · FY2003 · HL
Transfusion/Hemostasis Clinical Research Network$300,000
U01 · FY2002 · HL